Organ or Tissue Function
Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials
CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK
Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline
NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation: